* On November 21, 2014, the Committee for Medicinal for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Exviera® (dasabuvir) for the treatment of chronic hepatitis C virus (HCV) infection in adults in combination with other medicinal products for the treatment of chronic hepatitis C. Exviera® was evaluated under EMA’s accelerated assessment mechanism, a tool which aims to speed up patients’ access to new medicines where there is an unmet medical need.